Immutep and Lonza entered an agreement for cell line selection, master cell banking and process development of ImmuFact IMP321. Lonza will initiate the process development for the product using Immutep’s newly developed cell lines. IMP321 has been studied in Phase I/II trials as an oral presentation in a chemo-immunotherapy protocol in first-line metastatic breast cancer.   “We are pleased to support Immutep’s development initiatives,” said Janet White, head of Lonza development services. “This ...